When was PATH EX founded?

PATH EX was founded in 2016 and raised its 1st funding round 1 year after it was founded.

Where is PATH EX located?

PATH EX is headquartered in Nashville, United States.

Who is the current CEO of PATH EX?

Sinead Miller of PATH EX. They have also founded 1 company.

How many employees does PATH EX have?

As of Jul 31, 2026, the latest employee count at PATH EX is 8.

Is PATH EX a funded company?

PATH EX is a funded company, having raised a total of $5M across 6 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jul 01, 2017.

When was the latest funding round of PATH EX?

PATH EX's latest funding was a $***** Series A round on May 08, 2025, with participation from 3 investors.

Where does PATH EX rank among its competitors?

PATH EX ranks 8th amongst 31 active competitors, of which 8 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Amferia, which secured $4.11M in Dec, 2025.

Who are the top competitors of PATH EX?

PATH EX's top competitors include Aethlon Medical, Amferia and Cerus. Among them, Amferia secured the most recent funding round in December, 2025.

PATH EX - 2026 Company Profile, Team, Funding & Competitors

Company Details

PATH EX is developing a blood-cleansing device to remove pathogens from circulating blood. They are developing an extracorporeal blood-cleansing device designed to remove multi-drug resistant bacteria and bacterial endotoxin from circulating blood. its Pre-clinical studies demonstrated a reduction of 95% bacteria in a single pass.

Website: pathex.co
Social

Key Metrics

Founded Year

2016

Location

Nashville, United States

Stage

Series A

Total Funding

$5M in 6 rounds

Latest Funding Round

Series A, May 08, 2025, $*****

Investors

IAG Capital Partners & 10 more

Ranked

8^th among 31 active competitors

Employee Count

8 as on Jul 31, 2026

Similar Companies

Aethlon Medical & 33 more

View PATH EX's full profile

PATH EX has raised a total funding of $5M over 6 rounds. Its first funding round was on Jul 01, 2017. Its latest funding round was a Series A round on May 08, 2025 for $*****. 3 investors participated in its latest round. PATH EX has 11 institutional investors.

Here is the list of recent funding rounds of PATH EX:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 08, 2025	2232411	Series A	4619926	4342593	5616132	9039084
Sep 23, 2021	5715168	Grant (prize money)	8417430	9694748	4527656	MedTech Innovator
Oct 22, 2020	4270613	Grant (prize money)	2362421	9440929	2574451	MassChallenge

Access funding benchmarks and valuations. Sign up today!

View details of PATH EX's funding rounds and investors

The founders of PATH EX is Sinead Miller. Sinead Miller is the CEO of PATH EX.

Here are the details of PATH EX's key team members:

Sinead Miller: Co-Founder & CEO of PATH EX.
Contact Info: 1 email address

View details of PATH EX's Founder profiles and Board Members

PATH EX's employee count trend

PATH EX has 8 employees as of Jul 26. Here is PATH EX's employee count trend over the years:

Uncover PATH EX's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of PATH EX include Aethlon Medical, Amferia and Cerus. Here is the list of Top 10 competitors of PATH EX, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Aethlon Medical 1999, San Diego (United States), Public	Immunotherapeutic device company combating cancer and life-threatening viral infections	-	NIH, HHS	55/100
2nd	Amferia 2018, Gothenburg (Sweden), Series B	Developer of an anti-infective technology	$7.56M	Almi Invest, Chalmers Ventures & 5 others	55/100
3rd	Cerus 1991, Concord (United States), Public	Provider of pathogen inactivation technology for blood center or hospital blood bank	-	MidCap Financial, Apollo Investment Corporation ... & 3 others	54/100
4th	Cel-Sci 1983, Vienna (United States), Public	Developer of immunotherapy products for the treatment of cancer and infectious diseases	-	Alpha Capital Partners, Midsummer Capital ... & 7 others	53/100
5th	Ondine Biomedical 1999, Vancouver (Canada), Public	Developer of anti-infective therapies for a broad spectrum of bacterial, viral and fungal infections	$798K	Springboard Enterprises	49/100
6th	ARTCLINE 2007, Germany, Series A	Developer of immune cell-based extracorporeal therapies for intensive care medicine	$4.75M	-	47/100
7th	Z-App Kit 2007, Hafnarfjordur (Iceland), Unfunded	Developer of a amplifier and app for killing pathogenic microorganisms	-	-	45/100
8th	PATH EX 2016, Nashville (United States), Series A	Developing blood-cleansing device to remove pathogens from circulating blood	$5M	IAG Capital Partners, JLABS & 9 others	40/100
9th	Larada Sciences 2006, Salt Lake City (United States), Series A	Leading head lice treatment clinics offering fast, safe, effective solutions	$4.46M	Tech Coast Angels, ventureCapital.org & 1 others	36/100
10th	ToeFX 2016, Hamilton (Canada), Seed	Company discovering and developing treatment of toenail fungus (onychomycosis)	$30K	Accelerator Centre, The Forge	35/100